Depomed’s Proquin XR Ciprofloxacin Formulation Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Proquin XR’s more gradual release of dosage leads to a more advantageous adverse event profile than other ciprofloxacin products, Depomed says. The company is seeking a marketing partner and expects to launch its extended-release ciprofloxacin by year-end.
You may also be interested in...
Esprit Pharma Plans November Launch Of Proquin XR Following Licensing Deal
Esprit’s 100 sales reps will initially target marketing efforts to 8,000 urologist offices, with eventual movement to ob/gyn and family practitioners.
Esprit Pharma Plans November Launch Of Proquin XR Following Licensing Deal
Esprit’s 100 sales reps will initially target marketing efforts to 8,000 urologist offices, with eventual movement to ob/gyn and family practitioners.
Cipro Generics Approved; Dr. Reddy's Gets Exclusivity On 100 Mg Strength
FDA approves 14 ANDAs for the Bayer antibiotic in the 250 mg, 500 mg and 750 mg tablet strengths. Dr. Reddy's is the only ANDA filer to receive approval for the 100 mg dose.